Paul Kelly Marcom, MD

Professor of Medicine
Member of the Duke Cancer Institute
Campus mail 10 Bryan Searle Drive, Room 461 Seeley G. Mudd Building, Durham, NC 27710
Phone (919) 684-3877
Email address marco001@mc.duke.edu

Basic Science:
-Germline and somatic genetic changes in breast cancer.

Translational:
-Identification and management of individuals and families with hereditary cancer risk.
-Communication of cancer risk information to individuals and families.
-Breast cancer prevention.
-Optimizing management of early breast cancer.
-Treatment of metastatic breast cancer

Clinically, Dr. Marcom works as a medical oncologist in the multidisciplinary breast cancer clinic. He participates in clinical trials investigating new chemotherapeutic and biologic treatments. In addition, he is developing a new high risk, familial cancer clinic. This clinic will see patients and families thought to be at high risk of developing malignancies, and will interface with the forming Cancer Genetics Network. Patients and families will be counseled about their cancer risk, and identified for studying issues related to cancer genetics: determining penetrance of identified gene mutations, determining factors modifying genetic risk, prevention studies, etc. Finally, he also plans to be involved in clinical evaluation of drugs for treating breast cancer.

Areas of developing expertise include cell cycle alterations in malignancy, breast cancer, and hereditary cancer genetics.

Breast cancer, cell cycle, genetics, familial cancer, prognostic factors, angiogenesis

In Their Words

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1992 - 1995
  • Medical Resident, Medicine, Duke University, 1989 - 1992
  • M.D., Baylor University, 1989

Publications

Fayanju, Oluwadamilola M., Karine Yenokyan, Yi Ren, Benjamin A. Goldstein, Ilona Stashko, Steve Power, Madeline J. Thornton, P Kelly Marcom, and E Shelley Hwang. “The effect of treatment on patient-reported distress after breast cancer diagnosis..” Cancer, May 23, 2019. https://doi.org/10.1002/cncr.32174.

PMID
31120575
Full Text

Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study..” Clin Cancer Res 25, no. 9 (May 1, 2019): 2725–36. https://doi.org/10.1158/1078-0432.CCR-18-3102.

PMID
30635338
Full Text

Bellon, Jennifer R., Hao Guo, William T. Barry, Chau T. Dang, Denise A. Yardley, Beverly Moy, P Kelly Marcom, et al. “Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)..” Breast Cancer Res Treat, April 19, 2019. https://doi.org/10.1007/s10549-019-05238-4.

PMID
31004299
Full Text

Kikuchi, Robin, Gloria Broadwater, Rebecca Shelby, Jessica Robertson, Leah L. Zullig, Bailey Maloney, Claudia Meyer, et al. “Detecting geriatric needs in older patients with breast cancer through use of a brief geriatric screening tool..” J Geriatr Oncol, April 17, 2019. https://doi.org/10.1016/j.jgo.2019.04.010.

PMID
31005647
Full Text

Sitlinger, Andrea, Rebecca A. Shelby, Alyssa N. Van Denburg, Heidi White, Sarah N. Edmond, Paul K. Marcom, Hayden B. Bosworth, Francis J. Keefe, and Gretchen G. Kimmick. “Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer..” J Geriatr Oncol 10, no. 2 (March 2019): 317–21. https://doi.org/10.1016/j.jgo.2018.11.008.

PMID
30553719
Full Text

Mazurowski, Maciej A., Ashirbani Saha, Michael R. Harowicz, Elizabeth Hope Cain, Jeffrey R. Marks, and P Kelly Marcom. “Association of distant recurrence-free survival with algorithmically extracted MRI characteristics in breast cancer..” J Magn Reson Imaging, January 22, 2019. https://doi.org/10.1002/jmri.26648.

PMID
30672045
Full Text

Cain, Elizabeth Hope, Ashirbani Saha, Michael R. Harowicz, Jeffrey R. Marks, P Kelly Marcom, and Maciej A. Mazurowski. “Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set..” Breast Cancer Research and Treatment 173, no. 2 (January 2019): 455–63. https://doi.org/10.1007/s10549-018-4990-9.

PMID
30328048
Full Text

Saha, Ashirbani, Michael R. Harowicz, Elizabeth Hope Cain, Allison H. Hall, Eun-Sil Shelley Hwang, Jeffrey R. Marks, Paul Kelly Marcom, and Maciej A. Mazurowski. “Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival..” Breast Cancer Res Treat 172, no. 1 (November 2018): 123–32. https://doi.org/10.1007/s10549-018-4879-7.

PMID
29992418
Full Text

Force, Jeremy, Lynn J. Howie, Sara E. Abbott, Rex Bentley, P Kelly Marcom, Gretchen Kimmick, Kelly Westbrook, et al. “Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype..” Clin Breast Cancer 18, no. 5 (October 2018): 410–17. https://doi.org/10.1016/j.clbc.2018.02.010.

PMID
29615305
Full Text

McRee, Autumn J., Paul K. Marcom, Dominic T. Moore, William C. Zamboni, Zachary A. Kornblum, Zhiyuan Hu, Rachel Phipps, et al. “A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer..” Clin Breast Cancer 18, no. 4 (August 2018): 289–97. https://doi.org/10.1016/j.clbc.2017.10.014.

PMID
29153866
Full Text

Pages